These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2397623)

  • 1. The changing face of severe scleroderma in five patients.
    Spooner MS; LeRoy EC
    Clin Exp Rheumatol; 1990; 8(4):341-5. PubMed ID: 2397623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal complications and scleroderma renal crisis.
    Denton CP; Lapadula G; Mouthon L; Müller-Ladner U
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii32-5. PubMed ID: 19487221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Involvement in Systemic Sclerosis: An Update.
    Chrabaszcz M; Małyszko J; Sikora M; Alda-Malicka R; Stochmal A; Matuszkiewicz-Rowinska J; Rudnicka L
    Kidney Blood Press Res; 2020; 45(4):532-548. PubMed ID: 32521536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.
    Steen VD; Medsger TA
    Arthritis Rheum; 1998 Sep; 41(9):1613-9. PubMed ID: 9751093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleroderma renal crisis sine scleroderma.
    Canet JJ; Castañé J; Alvarez M; Nava JM; Llibre J
    Nephron; 2002 Jan; 90(1):119-20. PubMed ID: 11744818
    [No Abstract]   [Full Text] [Related]  

  • 6. Scleroderma renal crisis.
    Mouthon L; Bussone G; Berezné A; Noël LH; Guillevin L
    J Rheumatol; 2014 Jun; 41(6):1040-8. PubMed ID: 24833760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of acute pharmacological blockade of the renin-angiotensin system on intrarenal hemodynamics in patients with systemic lupus erythematosus and systemic scleroderma].
    Bugrova OV; Kutyrina IM; Bagirova VV; Morozova EV; Gromova MM
    Ter Arkh; 2001; 73(6):20-5. PubMed ID: 11521515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.
    Moinzadeh P; Riemekasten G; Siegert E; Fierlbeck G; Henes J; Blank N; Melchers I; Mueller-Ladner U; Frerix M; Kreuter A; Tigges C; Lahner N; Susok L; Guenther C; Zeidler G; Pfeiffer C; Worm M; Karrer S; Aberer E; Bretterklieber A; Genth E; Simon JC; Distler JH; Hein R; Schneider M; Seitz CS; Herink C; Steinbrink K; Sárdy M; Varga R; Mensing H; Mensing C; Lehmann P; Neeck G; Fiehn C; Weber M; Goebeler M; Burkhardt H; Buslau M; Ahmadi-Simab K; Himsel A; Juche A; Koetter I; Kuhn A; Sticherling M; Hellmich M; Kuhr K; Krieg T; Ehrchen J; Sunderkoetter C; Hunzelmann N;
    J Rheumatol; 2016 Jan; 43(1):66-74. PubMed ID: 26568599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function in noninsulin-dependent diabetes mellitus patients treated with angiotensin-converting enzyme inhibitors and calcium channel blockers.
    Nosadini R; Brocco E; Saller A; Cernigoi AM; Abaterusso C; Bortoloso E; Dalla Vestra M; Maioli M; Piarulli F; Fioretto P
    J Hypertens Suppl; 1998 Sep; 16(4):S27-32. PubMed ID: 9817189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of systemic sclerosis.
    Allanore Y; Kahan A
    Joint Bone Spine; 2006 Jul; 73(4):363-8. PubMed ID: 16495105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E; Orth SR; Strzelczyk P
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for systemic sclerosis.
    Steen V
    Autoimmun Rev; 2006 Feb; 5(2):122-4. PubMed ID: 16431341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features and prognosis of patients with scleroderma renal crisis].
    Roda-Safont A; Simeón-Aznar CP; Fonollosa-Plà V; Segarra-Medrano A; Vilardell-Tarrés M
    Med Clin (Barc); 2011 Oct; 137(10):431-4. PubMed ID: 21596402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Normotensive scleroderma renal crisis].
    Villaverde M; González A; Orellano P; Lafage M
    Medicina (B Aires); 2003; 63(1):49-50. PubMed ID: 12673962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
    Rockx MA; Haddad H
    Curr Opin Cardiol; 2007 Mar; 22(2):128-32. PubMed ID: 17284992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.
    Walker KM; Pope J; ;
    Semin Arthritis Rheum; 2012 Aug; 42(1):42-55. PubMed ID: 22464314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of scleroderma].
    Mouthon L
    Rev Prat; 2002 Nov; 52(17):1915-7. PubMed ID: 12532869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory: new trends in the treatment of the patient with systemic sclerosis.
    Valentini G; Cerinic MM
    Expert Opin Emerg Drugs; 2008 Jun; 13(2):227-36. PubMed ID: 18537518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.